A new test to help select colorectal cancer therapy is the first in a menu of rapid cartridge-based tests the firm is planning to support cancer testing.
The companies will use Abbott's RT-PCR Simpli-Collect STI Test for detection and differentiation of the causes of sexually transmitted infections.
The test supports rapid diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.
The test is a bead-based multiplexed immunoassay that also utilizes a machine learning classifier to determine whether a patient has Lyme disease.
The test uses autofluorescent single-walled carbon nanotubes to detect bacterial cell death in antimicrobial-containing microfluidic channels.
The company recently published a study showing that elemental patterns in single strands of hair are different in patients ...
The US District Court for the District of Delaware announced the settlement this week, ending the dispute, which originated as a patent infringement suit by Invitae against Natera.
The company plans to launch in 2026 a program that will provide labs with scanners free of charge in exchange for volume-based payments for biomarker tests.
The grant will support the development of an automated, cartridge-based desktop testing instrument for direct-from-blood detection of yeast infections.
The private equity firms invested along with executive Cary Breese, who is slated to become CEO of the clinical lab.
The agency said that during emergencies it will balance the risks of delaying access to tests compared with the risks of harm from inaccurate test results.
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback